News

JustRight Surgical® first company to receive FDA clearance for use of device in pediatric patients

Wednesday, June 29, 2016

LOUISVILLE, Colo., June 29, 2016 /PRNewswire/ -- JustRight Surgical, LLC, the pediatric medical device company, has received FDA clearance for specific use of their 3mm JustRight Vessel Sealing System in pediatric surgery. 

VisuGen Global Announces the Launch of the www.H20Profile.com Web Portal

Wednesday, June 29, 2016

Site was developed to help farmers comply with Food Safety Modernization Act Rule 
Continue Reading

Applications Being Accepted for AI Accelerator Grant Programs

Friday, June 24, 2016

The Colorado Office of Economic Development and International Trade is accepting applications for the first grant cycle of the Advanced Industries Accelerator grant programs for fiscal year 2017. Online applications are being accepted at www.advancecolorado.com/aiprograms for Proof of Concept grants and Early-Stage Capital & Retention grants. Applications will open July 1, 2016 and are due August 31, 2016. 

CBSA Highlights Breakthrough Treatments for the State’s Fast-Growing Baby Boomer and Millennial Populations

Tuesday, June 21, 2016

New Issue of Bioscience Colorado Magazine Shows How State’s Demographic Changes are Inspiring New Treatments, Cures 
Continue Reading

SomaLogic announces levels of nine blood proteins accurately predict which patients with stable coronary heart disease are at high or low risk of serious cardiovascular events

Tuesday, June 21, 2016

Academic/industry partnership reveals a truly personalized approach to managing individual patients with coronary heart disease 
Continue Reading

Prima-Temp Wins Global 1776 Challenge Cup Finalist Cash Award

Friday, June 17, 2016

Prima-Temp announced today it placed in the top 3 amongst over 1,000 global innovative companies at the annual Challenge Cup 1776 finals. 

AmideBio CTO Dr Michael Stowell to present a poster at 76 American Diabetes Association in New Orleans on June 11, 2016

Friday, June 10, 2016

BOULDER, CO, June 10, 2016 – AmideBio, LLC, a privately held biopharmaceutical company, announced that AmideBio’s CTO, Dr. Michael H. B. Stowell is going to present a poster titled SPARSE MATRIX SAMPLING OF ANTI-FIBRILLATION SEQUENCE MUTATIONS YIELDS A LIBRARY OF NOVEL SOLUTION STABLE GLUCAGON ANALOGS SUITABLE FOR AN ARTIFICIAL PANCREAS”.  

VetDC Announces Positive Results from TANOVEA Study in Dogs with Lymphoma

Tuesday, June 07, 2016

FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today announced the successful conclusion of a new field study of TanoveaTM (rabacfosadine), a novel small molecule therapy being developed as a treatment for lymphoma in dogs. This study evaluated the use of alternating Tanovea in combination with doxorubicin (a commonly used generic chemotherapy agent) every three weeks in 54 dogs with naïve multi-centric lymphoma, and found that this combination delivered an 81% response rate, with durations superior to doxorubicin alone, and comparable to that of multi-agent chemotherapy regimens. The Tanovea/doxorubicin combination was found to be generally safe and well tolerated in this study, with gastrointestinal and hematologic adverse effects being the most common events reported. 

Colorado BioScience Association Congratulates the 2016 Class of Boettcher Investigators

Tuesday, June 07, 2016

       

National Bioscience Report Shows Industry Creating Jobs and Driving Innovation

Tuesday, June 07, 2016

Bioscience industry contributing to U.S. economic growth and improving quality of life for patients 
Continue Reading